Lariciresinol (10 mg/kg, p.o., 3 weeks) displays anti-diabetic activity in Streptozotocin (HY-13753)-treated diabetic mice[6].
Lariciresinol (10-30 mg/kg, i.p., 28 days) inhibits complete Freund's adjuvant-induced arthritis in rats by regulating TGF-β and NF-κB pathways[7].
Lariciresinol (3-15 mg/kg body weight, p.o., daily, 9 weeks (tumor bearing rats); 20-100 ppm, diet, p.o., 5 weeks (E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors)) inhibits tumor growth and tumor angiogenesis in mammary tumor bearing rats and E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors[8].
| Animal Model: | Streptozotocin (HY-13753)-treated diabetic mice[6] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage (p.o.), 3 weeks |
| Result: | Decreased blood glucose levels and increased insulin levels.
Improved pancreatic islet size, increased GLUT4 expression.
Enhanced insulin signaling in skeletal muscle.
|
